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Recent advances in our understanding of the community structure and function of the human microbiome have
implicationsforthepotentialroleofprobioticsandprebioticsinpromotinghumanhealth.Agroupofexpertsrecently
met to review the latest advances in microbiota/microbiome research and discuss the implications for development
of probiotics and prebiotics, primarily as they relate to effects mediated via the intestine. The goals of the meeting
were to share recent advances in research on the microbiota, microbiome, probiotics, and prebiotics, and to discuss
these ﬁndings in the contexts of regulatory barriers, evolving healthcare environments, and potential effects on a
variety of health topics, including the development of obesity and diabetes; the long-term consequences of exposure
to antibiotics early in life to the gastrointestinal (GI) microbiota; lactose intolerance; and the relationship between
the GI microbiota and the central nervous system, with implications for depression, cognition, satiety, and mental
healthforpeoplelivingindevelopedanddevelopingcountries.Thisreportprovidesanoverviewofthesediscussions.
Keywords: microbiome; probiotics; prebiotics; intestinal microbiota; health disorders
Introduction
Majoradvanceshaveoccurredinourunderstanding
ofthecompositionandmetaboliccapabilitiesofmi-
crobialcommunitiesinthehumanbody,gainsmade
from revolutionary advances in DNA sequencing,
metagenomic analytical techniques, and computa-
tional biology. These strides have greatly increased
ourunderstanding ofthebacterialgenomespresent
in these microbial communities, the boundaries of
normal variation, and how variations in micro-
[∗Correction added after publication 26 November 2013:
an error in this afﬁliation was amended.]
bial composition are associated with pathology and
disease. Indeed, the number of published studies
onmicrobiome-relatedresearchhasincreasedfour-
fold between 2005 and 2012. Much remains to be
learned, however, about how to translate this infor-
mation to probiotic or prebiotic interventions that
may modify the microbiome and promote human
health.
A one-day conference, “Probiotics, Prebiotics,
and the Host Microbiome: the Science of
Translation,”1 hosted by the New York Academy of
Sciences,theSacklerInstituteforNutritionScience,
andtheInternationalScientiﬁcAssociationforPro-
biotics and Prebiotics (ISAPP), including experts in
doi: 10.1111/nyas.12303
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the ﬁelds of microbiome research, probiotics, and
prebiotics, met on June 12, 2013 in New York City
to review the latest research on these topics, dis-
cusstheimplicationsforpublichealth,andincrease
communication and collaboration. The conference
was divided into ﬁve sessions and included oral and
visual presentations, as well as a panel discussion.
Putting probiotics, prebiotics, and the
microbiome into translational context
The conference opened with a presentation by John
Hutton (University of York, United Kingdom) on
the economic challenges associated with probiotic-
and prebiotic-based interventions. Hutton said that
during the past 20 years economic evaluation has
become a widespread practice in the pharmaceu-
tical sector, including cost versus beneﬁt analyses
to aid decision making about utilization and reim-
bursement of disease treatments.2 In fact, health
technology assessment (HTA), including the
demonstration of the cost-effectiveness of new
products, has become an essential tool for gauging
thevalueofdrug-basedapproachesworldwide.The
economic evaluation methods used in comprehen-
sive HTA consider a number of elements, including
clinical (e.g., efﬁcacy and safety), economic, social
(equity of access), and political (incentive for inno-
vation) aspects.
The value of nutrition for achieving improved
health outcomes has become recognized. Conse-
quently, nutritional products are now considered
to be a health technology. However, the economic
evaluation methods used in HTA are more difﬁ-
cult to apply in the context of nutrition, where
reduction of disease risk is the most frequent aim.
It appears unlikely that HTA methods can be used
to bridge the boundary between drug and food
(including probiotics and prebiotics) in the imme-
diate future because of the difference in endpoints
needed for supporting data in each category. Addi-
tional clarity is needed on the business model for
economic evaluation of general public and disease
prevention beneﬁts, compared to disease treatment
claims.Fordisease-speciﬁcinterventions,higherev-
idential standards will be expected in jurisdictions
wherehealthcaresystemfundingissought.Formore
general interventions to change dietary behavior, as
with many public health policies, the beneﬁts in
terms of disease-risk reduction may not be realized
until well into the future. HTA in this context relies
on modeling and projections of costs and beneﬁts,
andissubjecttomanyuncertaintiesthatcanonlybe
reducedbythecollectionoflong-termepidemiolog-
ical data linking interventions with lifetime health
outcomes. However, some HTA agencies, such as
theNationalInstituteforHealthandClinicalExcel-
lence (NICE) in England and Wales, are developing
methods to address the analytical and data issues.
Assessment of the economic feasibility of pro-
biotic or prebiotic interventions is further compli-
cated by the variability in products, intervention
protocols, local study procedures, populations tar-
geted and trial outcomes. These differences must
be addressed across centers to allow advancement
of tools in the domain of probiotics and prebiotics.
Going forward, the approach described by White-
head et al.3 for assessing the economic viability of
a nutritional intervention for irritable bowel syn-
drome (IBS) might serve as a good model for eval-
uatingprobiotic-orprebiotic-basedinterventions.a
In order for economic evaluation of probiotics and
prebiotics as nutritional interventions to succeed,
quality data (especially involving disease interven-
tions), behavioral changes by individuals, and eco-
nomicdriversmustbecomepartoftheoverallhealth
outcome process.
Programming the microbiome
Metagenomic studies of the human intestinal mi-
crobiome reveal that the human gut carries, on
average, about 540,000 microbial genes, represent-
ing the dominant microbes in this ecosystem.4 Ap-
proximately 55% of these genes constitute the core
metagenome (i.e., are genes shared among at least
50%ofindividuals),whilemanyothergenesappear
to be unique and/or present in less than 20% of
individuals.
The second conference session, moderated by
David Mills (University of California, Davis), had
presentations on the early development of the in-
testinal microbiota and how ﬂuctuations in the
human microbiome can correlate with changes in
human health. The aim of the session was to pro-
vide an overview of the initial programming of the
aTheseeconomicevaluations,however,areusefulonlyfor
health effects that are sufﬁciently substantiated; for IBS,
for example, see Hungin etal., 2013. Alimentary Pharma-
cology & Therapeutics. doi:10.1111/apt.12460.
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intestinal microbiota and how environmental fac-
tors or therapeutics can alter the composition and
contribute to various metabolic disease states.
David Relman (Stanford University School of
Medicine) opened the session with a perspec-
tive as an infectious disease specialist and clinical
researcher interested in variation in microbial di-
versity patterns as a function of time (microbial
succession) and in response to perturbation. Rel-
man described the initial acquisition and develop-
ment of the gut microbiota during the early weeks
oflife,andemphasizedits signiﬁcantroleinhuman
health and disease. In addition to contributing to
food digestion and nutrition and the regulation of
metabolism,thegutmicrobiotaisinvolvedindevel-
opment and terminal maturation of host mucosa,
regulationofimmunesystemtargetrecognitionand
responses, and resistance to colonization and in-
vasion by pathogens. Humans are born essentially
devoid of an intestinal microbiota, but this highly
important ecological system is soon acquired after
birthandeventuallycomprisesover90%ofthecells
of the human adult. Despite the advances in tools
and techniques for studying the human gut micro-
biome,anumberofquestionsremainaboutitsearly
acquisition and succession.
Relman and colleagues study the assembly of the
gut, oral, and skin microbiota of infants during
the ﬁrst several years of life to better understand
the development of habitat speciﬁcity and the fac-
tors underpinning compositional variation during
this critical timespan. Multiple factors appear to in-
ﬂuence the early succession of the gut microbiota
in individual infants, including mode and timing
of birth, host genetics, diet, environmental expo-
sures (other humans, animals, medications), and
health status. Evidence from a number of studies
indicates that the fecal microbiota of the vaginally
delivered newborn resembles that of the maternal
gastrointestinal tract or vagina, while that of
cesarean-delivered newborns resembles that of the
maternal skin.5,6 Various taxonomic groups are ac-
quired early during a window of permissivity and
persistovertime,possiblyundergoingshiftsinpop-
ulationfromdominanttosubdominant,whileother
taxonomic groups may be acquired later or dis-
appear altogether (Fig. 1). Recent studies using
cultivation-independent evaluation of the fecal mi-
crobiota of premature infants have revealed a low
level of diversity, high inter-individual variability,
and a capacityforabrupt temporal shiftsin species-
and strain-level composition. The long-term effects
of these differences are not fully understood. A key
emerging question in the ﬁeld is how these early
lifedifferencesinmicrobiotadevelopmentinﬂuence
health through childhood and later in life.
Evaluation of the compositional structure of the
infant gut microbiota over time indicates that eco-
logical states persist for days or weeks, followed by
abrupt transitions to alternative states. These dis-
tinctive, successive equilibrium states are observed
inbothpretermandtermbabies,althoughthecom-
position of their communities differ signiﬁcantly
at the earliest days of life. Periods of stable phy-
logenetic composition at the taxonomic level of
genus and species may belie underlying shifts in
the abundances of strains with different functional
potential.7 Biﬁdobacteria eventually appear in most
babies, typically detected between 1 and 2 months
of life. In general, members of enterobacteria and
biﬁdobacteria appear early on, Bacteroides spp. at
about the middle of the ﬁrst year, and butyrate-
producing Faecalibacterium and Roseburia toward
the end of the ﬁrst year of life. Considerable intra-
and interpersonal variation in fecal bacterial com-
munity structures is observed during the ﬁrst year
of life, and intrapersonal variation decreases as a
function of age.5 The emergence of an adult-like
microbiota pattern occurs by the third year.8 While
changes in diet appear to be associated with major
shifts in the structure of the infant microbial com-
munities, the relative role of other variables (e.g.,
medications, nutrition, phages, parasitic burden) is
not well understood.
Martin Blaser (New York University School of
Medicine) is leading a research effort on the de-
velopmental pathway for the microbiome during
early life, exploring how perturbations may in-
ﬂuence later risk of various disorders.9 During
his presentation, “Impact of antibiotic exposures
on the developing microbiota,” Blaser reminded
the audience that medical interventions can affect
the composition of the microbiota, with poten-
tial effects on metabolic and immunologic devel-
opment.Examplesincludeantibioticsadministered
to mothers or infants, cesarean delivery, and use of
basic infant formula. The collective effects of these
exposures, over time and following transmission
from exposed mothers to infants, may reduce the
diversityofthegutmicrobiota.Low-doseantibiotics
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Figure 1. Relative changes in community structure and composition of the intestinal microbiota in early life. (A) Vertical lanes
correspond to sample days, and gray-shaded boxes represent the relative abundance of different taxonomic groups. (B) Relative
abundances of major bacterial phyla represented in each sample. (C) Signiﬁcant events with relevance to the infant’s diet that may
have inﬂuence on microbiota changes. From Koenig JE, et al.54
have been used to enhance weight gain and growth
of livestock, so early exposure to antibiotics could
inﬂuence the risk of obesity, metabolic syndrome
and associated conditions in humans.10 A striking
correlationisobservedwhencomparinggeographic
distribution patterns in the United States for rates
of obesity and antibiotic use (Fig. 2), although the
causal relationship is unknown.
Tostudytheeffectsofearlymicrobiomeperturba-
tion, Blaser and colleagues have developed animal
models to evaluate the effects of continuous sub-
therapeutic antibiotic treatment from pre-weaning
to adulthood (STAT model) or pulsed antibiotic
treatment for 3–5 day periods at developmental
stages of late pre-weaning, weaning, and adulthood
(PAT model) on gut microbiota composition and
other developmental factors. These studies have
shown short-term changes in the microbiota com-
position of the ileum and colon, and liver adiposity
and lipogenesis gene expression, as well as long-
termeffectsonhostmorphometry,metabolism,and
immune cell populations.9 The results suggest that
antibiotic exposures in early life not only affect the
developing microbiota, but also may affect the risk
of obesity, metabolic syndromes, and autoimmune
diseases.
A number of other reports have drawn atten-
tion to an association between alterations in the
intestinal microbiota and obesity or insulin re-
sistance. In his presentation titled, “When the
programming goes awry: diabetes, obesity, and be-
yond,” Patrice D. Cani (Universit´ e catholique de
Louvain, Belgium) discussed how disruptions in
theprogrammingofgutmicrobiotamaycontribute
to the development of obesity and type 2 diabetes
(T2D). While a number of studies have associated
changes in the gut microbiome with metabolic dis-
eases, the causality remains to be proven in hu-
mans. Cani described studies into the mechanism
underlyingthisassociation,andspeciﬁcallythecon-
ceptofmetabolicendotoxemia—thatis,anincrease
in plasma lipopolysaccharide (LPS) levels—as one
of the triggering factors that can lead to the de-
velopment of metabolic inﬂammation and insulin
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Figure 2. Comparisons between the geographical distribution of obesity (left) and antibiotic use in the United States, 2010
(right). Obesity trend data were from the CDC Behavioral Risk Factor Surveillance System (http://www.cdc.gov/brfss/). Antibiotic
prescriptions were from a national survey of out-patient pharmacy records, as described by Hicks, et al.55
resistance associated with obesity.11 High-fat di-
ets have been shown to alter the gut microbiota
composition. Cani and colleagues have previously
demonstrated that mice treated with antibiotics are
resistant to diet-induced metabolic endotoxemia,
fatmassdevelopment,metabolicinﬂammationand
insulin resistance.12 Similarly, several studies have
demonstrated that germ-free (GF) mice are pro-
tected against glucose intolerance, metabolic in-
ﬂammation, and insulin resistance, which suggests
that the microbiota may be involved.13,14 The mi-
crobiota of high-fat–fed mice or obese (ob/ob)m u -
tant mice can also transfer the obesity/T2D pheno-
type to ex-GF mice.13,15 Other studies have shown
that antibiotic treatment protects mice from this
diet-induced obesity,12,16 while prebiotics lead to
reduced body-weight gain and fat deposition and
protect against hepatic steatohepatitis in obese and
T2D rats.17 Cani and colleagues have shown that
nutritional or genetic-induced obesity and type 2
diabetic rodents display gut barrier dysfunctions
leading to the leakage of LPS and possibly other
microbiota-derived factors.12 They found that gut
microbiota metabolites can interact with the en-
docannabinoid system,18 as well as with enteroen-
docrine L cells to alter gut permeability (Fig. 3),
possibly through production of GLP-1, PYY, and
GLP-2.19
Additional studies have used prebiotics and pro-
biotics to identify novel mechanisms of bacterial
interaction with the host that control gut perme-
ability and metabolism during obesity and T2D.
TheyshowedthatlevelsofAkkermansiamuciniphila
are decreased in the gut microbiota of mice fed
high-fat diets and in ob/ob mice, while feeding the
miceprebiotics(inulin-typefructans)restoresthese
populations.20 Transfer of A. muciniphila to high-
fat diet–induced obese mice led to decreased fat
mass gain, increased fat oxidation, and restored
gut barrier function in the colon. Viable, but not
heat-killed A. muciniphila, increased mucus layer
thickness, decreased plasma LPS levels, and coun-
teracted the diet-induced metabolic disturbances.20
These studies demonstrate that the gut microbiota
inﬂuences energy homeostasis; that bacterial com-
pounds contribute to low-grade inﬂammation and
gut permeability in obesity and T2D; and that cer-
taintypesofbacteriawithinthegutmicrobiota,such
asA.muciniphila,mayplayaroleinpreventingthese
obesity-related conditions.
Another perspective on the role of the gut mi-
crobiome in the development of metabolic disor-
ders was presented by Max Nieuwdorp (Univer-
sity of Amsterdam, the Netherlands). Nieuwdorp
and collaborators have been investigating the role
of the gut microbiota in health and disease us-
ing fecal transplantation. While fecal transplanta-
tion has been practiced for centuries, since 1958
only 500 case reports exist on treatment of patients
with recurrent Clostridium difﬁcile infection, IBS,
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Figure 3. Interactions between gut microbiota and the endocannabinoid system: impact on gut barrier function and metabolic
inﬂammation.Obesity(nutritionalorgenetic)isassociatedwithchangesinthegutmicrobiotacompositionandpathophysiological
changes, whereby the endocannabinoid system tone is altered. This phenomenon is associated with the development of gut per-
meability,metabolicendotoxemia,metabolicinﬂammation,andalteredadiposetissuemetabolism(adipogenesis).FromDelzenne
NM, et al.56
inﬂammatory bowel disease (IBD), or multiple
sclerosis.22 Modernproceduresinvolvebowellavage
for 4–6 hours followed by either colonoscopy or
duodenal infusion of fecal homogenates prepared
fromhealthyscreeneddonors(followingaquestion-
naire on bowel habits, travel history, medications,
andscreenedforanextensivelistoffecalandblood-
borne pathogens). A recent study by Van Nood
et al.21 showed a 92% cure rate, with an increase in
microbiota diversity for over 6 months, in patients
with recurrent C. difﬁcile infection.
Nieuwdorp and collaborators then conducted a
randomized controlled trial in obese subjects to in-
vestigate the effects of fecal transplantation on in-
sulin resistance using hyperinsulinemic euglycemic
clamp techniques and evaluation of gut microbiota
composition.22 Subjectswererandomizedtoreceive
fecal microbiota (FM) from homogenates of their
own feces (autologic) or from healthy, lean donors
(allogenic). Results showed a signiﬁcant improve-
ment in insulin sensitivity in subjects receiving al-
logenic FM lasting for up to 6 weeks, but no change
in those receiving autologic FM. Infusion of allo-
genic FM also led to changes in the composition
of the fecal and small intestinal microbiota (mostly
butyrate producers) and a reduction in fecal short
chain fatty acids (SCFA) butyrate and propionate.
No change was observed in food intake or weight
among groups; this is interesting, as obesity can re-
sult from increased food intake as well as altered
nutrient content. A more striking improvement
in insulin sensitivity was observed in one subject
following FM transplant from a speciﬁc allogenic
donor. This result correlated with higher levels of
Eubacteriumhallii (anaerobicGram-positiveFirmi-
cute) in the small intestine. Recognizing that other
studies have shown that certain groups within the
gut microbiota may have diagnostic and clinical
value in predicting T2D in obese patients (e.g.,
Roseburia species, Faecalibacterium prausnitzii,
Lactobacillus gasseri),23 Nieuwdorp et al. have since
investigated E. hallii and generated data suggesting
that four weeks of daily gavage with cultured
E.halliiinmaledb/dbmiceissafeandhasbeneﬁcial
effects on glucose metabolism, most likely through
altered fecal SCFA production.24 Additional studies
areplannedtoevaluatethesafetyandpotentialben-
eﬁts of E. hallii for improving insulin sensitivity in
humans.
Collectively,thesestudiessuggestthatthegutmi-
crobiota per se and certain bacterial products in
particular, play a role in the development of obesity
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and changes in insulin sensitivity. Future research
needs to conﬁrm causality in humans and clinical
relevance with respect to gut microbiota, as well as
explore mechanisms of action and use of probiotics
or prebiotics.
Translating research to transform health
care
Public health is confronted with complex systems
thathaveoutcomeswithmultipledeterminantsthat
interactinobscureways.Asaresult,changestopub-
lic health systems often lead to unintended conse-
quences. The third session, moderated by Gregor
Reid (Western University and Lawson Health Re-
search Institute, Canada), consisted of a keynote
presentationbyHarryBurns(ChiefMedicalOfﬁcer
for Health, Scotland) and a panel discussion that
considered potential pathways and issues involved
withtranslatingresearchadvancestoinﬂuencepub-
lic health policy. The goals of the session were to
understand the factors involved with inﬂuencing a
healthcare system—at the country, state/province,
or local community level—and discuss how best to
applythisknowledgeintransformingresearchﬁnd-
ings on probiotics and (to a lesser extent) prebiotics
to change public health policy.
In his keynote lecture, Burns provided examples
ofhowaqualityimprovementmodelunderhislead-
ership led to signiﬁcant reductions in hospital in-
fection rates (e.g., ∼90% reduction in C. difﬁcile),
hospital mortality rates, infant mortality rates, and
improved clinical record keeping. A key reason
stated for the success of this model was the involve-
ment and complete buy-in from hospital personnel
andotherkeyconstituents.Oneexampleofthiscol-
laboration is the Early Years Collaborative (EYC),25
whoseobjectiveistosupportanddrivepracticalac-
tion under a broader partnership program aimed at
deliveringasharedcommitmenttogivechildrenthe
best start in life and to improve the life chances of
children,youngpeople,andfamiliesatrisk.TheEYC
effort aims to (1) deliver measurable improvement
in outcomes and reduce inequalities for Scotland’s
vulnerable children; (2) put Scotland on course to
shift the balance of public services toward early in-
tervention and prevention by 2016; and (3) sustain
this change to 2018 and beyond. The strategy used
for implementing such changes involves the follow-
ing actions: understand the problem, build the will
forchange,executethechange,anddrivethechange
with data.
Theirmaintacticalapproachistodesignaninter-
ventionbaseduponsoundrationale(whethermed-
ical, scientiﬁc, or social), test it in a real situation,
measure and modify it, then continue until the im-
plementation is optimized. By building the will of
all the change makers, objectives can be met and
tangible improvements achieved.
Panel discussion
In translating these learnings to probiotics, Burns
and an expert panel, including Rowena Pullan
(Pﬁzer Consumer Health Care), Bruno Pot (In-
stitut Pasteur de Lille), and David Mills, restated
the importance of public–private partnerships to
drive public policy change. And while the strength
of evidence for probiotics is clear in a number of
applications26 (such as treating necrotizing entero-
colitisinprematureinfants,27 preventingantibiotic-
associated diarrhea,28 improving urogenital health
in women,29 and countering infection and allergy
relatedtorespiratoryhealth30,31),thesedataneedto
becollated,presentedtochangemakers,andusedas
a means to shift medical practice. This is currently
a major challenge in the United States, where any
product (including yogurt) being tested to treat,
prevent, or cure disease must be investigated as a
drug, while fewer barriers exist in Canada and other
countries.
General concern was expressed by the audience
abouttheregulatoryviewofprobioticfoodresearch
and how it can be used to substantiate market ap-
proval and claims. The regulatory approval path
for probiotic foods is complicated, particularly go-
ing through the FDA. Pot responded to questions
about the situation with probiotics at the European
Food Safety Authority (EFSA). He explained that
theEFSApositiononprobioticsisinconsistentwith
precedent established by other dietary substances.
For example, the data on the health beneﬁts of pro-
bioticsaremoreextensiveandofhigherquality(i.e.,
evaluating nonessential endpoints) than data for
most vitamins and minerals as health supplements
that have been accepted by the EFSA. Yet, no probi-
otic claims have been approved by this government
agency. Regulatory barriers now exist in the Euro-
pean Union to use of the word probiotic on foods. It
isseenasanunapprovedhealthclaim,andassuchis
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not allowed despite mounting scientiﬁc evidence of
beneﬁcialeffects.Thereareclearchallengeswiththe
regulatory framework in the United States and the
EuropeanUnion,butthoseinvolvedwithprobiotics
and prebiotics must continue to do quality research
and communicate the outcomes of that science in
more efﬁcient and effective ways.
A large gap currently exists in frontline health
care providers’ understanding of probiotics, pre-
biotics and the human microbiome, and certainly
on how to interpret the vast data sets from omics
studies. The beneﬁts of advances in microbiome re-
search and probiotics will only be realized when
new technologies from omics are integrated into
medical diagnostics, and when medical students,
physicians, and administrators are educated on the
healthbeneﬁtsandcost-savingspotentialfrompro-
biotics. Clear messages need to be crafted and di-
rected at key target audiences, such as consumers,
politicians, doctors, pharmacists, and others. One
new initiative, Gut Microbiota for Health,32 aims to
bridge this information gap with clinicians through
annualmeetingsandaninteractivewebsitewithba-
sicinformationonprobiotics/prebioticsandthegut
microbiome.Lessonsmightbelearnedfromsimilar
initiatives in the clinical ﬁeld, such as the European
PathoNGenTraceproject,whichaimstoextractuse-
fulfunctional(clinicallyrelevant)informationfrom
t h ew h o l eg e n o m es e q u e n c e . b
David Relman inquired about the cost to collect
the data needed for regulatory approval. Cost sav-
ings in health care are difﬁcult to evaluate. Burns
pointed out that although governments value cost-
savinginterventions,changesareoftenadoptedsim-
plybecausetheyimprovewell-beingandtheyarethe
right thing to do. Burns felt that the public is not
impressed by cost-effectiveness.
Impact of gut bacteria on brain
development, circuitry, and behavior
While many general press articles on gut microbes
discuss the apparent link to obesity, there has also
been a marked increase in discussions of gut–
brain interactions. Jane Foster (McMaster Univer-
sity, Canada) has been using conventional and GF
mice to study the gut–brain axis, which involves the
complex interplay between the autonomic and en-
bSee http://www.patho-ngen-trace.eu/
teric nervous systems, pituitary and gut hormones,
and the gut inﬂammatory systems (Fig. 4). Her
research uses a well-established behavioral test—
the elevated plus maze (EPM)—to examine ex-
ploratory behavior and is used to assess anxiety lev-
els. Typically, conventional mice spend most time
in closed-arm areas (harm avoidance) of the EPM
compared to open-arm areas. Extending from ear-
lier studies observing that GF mice show enhanced
stress-reactivity,33 Foster et al. found that GF mice
demonstrated reduced anxiety-like behavior in the
EPM (more time in open arms, both in duration
and numbers of visits), compared with speciﬁc
pathogen–free(SPF)mice.34,35 Thereducedanxiety
behavior persisted when GF mice were colonized
withSPFmicroﬂoraduringadulthood(ex-GF),but
notwhencolonizedatanearlierage,demonstrating
that gut–brain interactions inﬂuence central ner-
voussystemwiringearlyinlife.Thelowanxiety–like
phenotype was accompanied by long-term changes
in plasticity-related genes in the hippocampus and
amygdala.
The researchers have also been examining the
interplay of leptin and central circuits for stress-
reactivity and feeding in the presence or absence
of the gut microbiota. They found that leptin-
insufﬁciencyinGFmiceleadstolong-termchanges
in the expression levels of the brain’s leptin recep-
t o r s ,a sw e l la sc e r t a i np e p t i d e ss u c ha sn e u r o p e p -
tide Y (NPY), which inﬂuence corticosterone levels
and thus plays pivotal roles in the stress response.
The response of different strains of mice and the
role of serotonin or other feedback mechanisms are
unclear. While many questions remain, continued
work in this exciting area may shed light on how
developmentalfactorsandtheintestinalmicrobiota
inﬂuence the interface between metabolic diseases
and mood disorders.
Gary Frost (Imperial College London, United
Kingdom)reportedonanotherareaofstudyregard-
ing the effects of gut microbiota on brain activity,
namely, the effect of dietary prebiotics and asso-
ciated production of SCFAs such as acetate, pro-
pionate, and butyrate on hypothalamic neuronal
activityandobesity.Itiswidelybelievedthatthein-
creasing incidence of obesity is associated with low
consumption of fermentable ﬁbers and high intake
ofdietarycarbohydrates.Frostandcolleaguesarein-
vestigatingthemechanismsinvolvedinthedecrease
inbodyweightandimprovedinsulinsensitivitythat
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Figure 4. Pathways involved in bidirectional communication between the gut microbiota and the brain. Multiple pathways exist
through which the gut microbiota can modulate the gut–brain axis. They include endocrine (cortisol), immune (cytokines), and
neural(vagusandentericnervoussystem)pathways.Thebrainrecruitsthesesamemechanismstoinﬂuencethecompositionofthe
gutmicrobiota,forexample,underconditionsofstress.Thehypothalamus–pituitary–adrenalaxisregulatescortisolsecretion,and
cortisol can affect immune cells, alter gut permeability and barrier function, and change gut microbiota composition. Conversely,
the gut microbiota and probiotic agents can alter the levels of circulating cytokines, and this can have a marked effect on brain
function. Both the vagus nerve and modulation of systemic tryptophan levels are strongly implicated in relaying the inﬂuence of
the gut microbiota to the brain. In addition, short-chain fatty acids (SCFAs) are neuroactive bacterial metabolites of dietary ﬁbers
that can alsomodulate brainand behavior. ACTH, adrenocorticotropichormone; CRF, corticotropin-releasingfactor. From Cryan
and Dinan.57
occurs with increased intake of nonabsorbable fer-
mentable carbohydrate. Feeding mice high levels of
nonabsorbable fermentable carbohydrate leads to
decreased adiposity and increased levels of plasma
GLP-1,oneofseveralanorecticgastrointestinalhor-
mones produced by enteroendocrine L cells in the
colon,andcapableofsuppressing neuronal activity.
Animal studies have shown that enteroendocrine L
cellscontainGprotein–coupledSCFAreceptorsand
release gut hormones such as GLP1 and PYY.36 Us-
ing a primary colonic cell model, Frost et al.f o u n d
that SCFAs stimulate PYY release from human pri-
mary L cells. In other studies, they demonstrated
that acetate decreases appetite in mice following
intraperitoneal administration, is capable of cross-
ing the blood–brain barrier, and has a direct effect
on the hypothalamic arcuate nucleus stimulating
anorectic signals. These observations are consistent
with the hypothesis that SCFAs have positive bio-
logical effects involved with improved appetite reg-
ulationandglucosehomeostasis.Additionalstudies
are planned to evaluate the effects of direct colonic
deliveryofSCFAs(e.g.,propionateesters)onrelease
ofguthormonesandappetiteregulationinhumans.
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Helen E. Raybould (University of California,
Davis)described hergroup’sworkonthegut–brain
axisasitrelatestoregulationofGIfunctionandfood
intake. Luminal chemosensors found on enteroen-
docrine cells that line the intestine transmit signals
tothecentralnervoussystem(CNS)viathevagalaf-
ferentneurons,whichinturninﬂuenceGIfunction
through parasympathetic pathways and eating be-
haviorthrougheffectsonhigherbraincenters.Stud-
ies were designed to evaluate changes in microbiota
and gut epithelial function that may be connected
withhormonalpathways.Thesepathways,whichin-
ﬂuence food intake and obesity, were assessed using
Sprague-Dawleyratsfedahigh-fatdiettoinduceei-
ther an obesity-prone (DIO-P) or obesity-resistant
(DIO-R) phenotype.37 Using bacterial 16S rRNA
measurements, they showed a decrease in total bac-
terial density and an increase in the relative propor-
tion of Clostridiales in high-fat–fed rats regardless
ofphenotype,whileanincreaseinEnterobacteriales
was only seen in the microbiota of DIO-P rats. The
DIO-P group also exhibited increases in intestinal
permeability,whichresultedinelevatedplasmaLPS
levels, and Toll-like receptor 4 activation. The data
suggest that DIO-P rats are unable to transmit sig-
nalstothebrainthatinvolvecholecystokinin(CCK)
regulation of vagal afferent neuron transmissions
to communicate satiety in response to food intake.
Further studies show that, compared with a normal
diet,paracellularpermeability,transcellularperme-
ability, and mucosal inﬂammation are increased by
feeding a Western diet and these changes can be
prevented by feeding Biﬁdobacterium infantis and
prebioticbovinemilkoligosaccharides(MOs).Col-
lectively,theseresultssuggestthatconsumptionofa
high-fat diet may induce changes in the gut micro-
biota and increase low-grade inﬂammation that ul-
timately contributes to the development of diabetes
and obesity. Additional investigations are expected
toclarifyhowspeciﬁcprebiotic/probioticcombina-
tionsmaymodulategutfunctionandinﬂammatory
responses to delay the onset of, or even prevent,
diabetes and obesity.
Reaching people in need with probiotics
and prebiotics
The ﬁnal session, moderated by Ruth Ley (Cornell
University), consisted of a series of short presenta-
tions with a focus on translating scientiﬁc innova-
tionsinpro-andprebioticstoreachthepeoplewith
the greatest needs. Andrew Serazin (Matatu, LLC)
set the stage by presenting the challenges involved
in these activities. Studies into the microbiome are
oneofthemostactiveareasofthelifesciencestoday,
according to Serrazin, since the isolation of restric-
tion enzymes nearly forty years ago. Shifting con-
sumer preferences and dietary patterns, at least in
the United States, underlie drastic changes in con-
sumption ofmajornutrient classeswithconcurrent
rises in chronic disease. Escalating healthcare costs
and demands of an aging population have led to
a growing preference for self-treatment or preven-
tion ofdiseaseincluding wellnessapproaches.Tobe
successful in developing widely distributed probi-
otic and prebiotic products, the surge of scientiﬁc
inquiryintothestructureandfunctionofthemicro-
biome must be matched by a focused and transpar-
ent effort to engage industry, health policy makers,
and the general public.
Extending such products to people in need in
emerging economies willpresent a whole new set of
challenges. Most of the world’s 7 billion people are
currentlyexperiencingsigniﬁcantalterationsindis-
easeburdens,dietarypatterns,andlifestyle.Thishas
been dramatically documented in countries such as
India and South Africa, where it is common to ﬁnd
high levels of both malnutrition-induced stunting
andobesityinthesamepopulation,whichisindica-
tive of nutritional deﬁcits that manifest in opposite
forms.
Products derived from advances in our under-
standing of the microbiome are part of an entirely
new ﬁeld at the union of nutrition and medicine,
and their applications are likely to be profound in
meeting future challenges in food and nutrition.
Successful translation of advances made in micro-
biome research to probiotic and prebiotic products
will require the following: (1) an open, engaged,
and realistic research community with clear goals,
including sharing of potential beneﬁts through
commitment to global access; (2) recognition that a
broad number of foods and ingredients shape mi-
crobiome structure and function and, in turn, can
affect the health of consumers; (3) regulation based
on meaningful biomarkers and deﬁned outcomes;
a n d( 4 )t r u s t e dp r o d u c t sw i t hac l e a rh e a l t hb e n e ﬁ t
to consumers.
Gregor Reid partnered with Patricia Hibberd
(Harvard Medical School and Massachusetts Gen-
eralHospital)inapresentationtitled,“Fromyogurt
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Figure5. Comparisonofworldwidedistributionoflifeexpectancypatternswithratesofmalnutrition-relatedmortality.Countries
with high death rates due to malnutrition are typically associated with low life expectancy. From Wikipedia: http://en.wikipedia.
org/wiki/File:Esperanza_de_vida.PNG; and World Health Rankings for death rates: http://www.worldlifeexpectancy.com/cause-
of-death/malnutrition/by-country/.
tovaccineforthedevelopingworld.”Reidexplained
that a striking relationship exists when comparing
global longevity patterns and mortality rates due to
malnutrition (Fig. 5). Countries in Africa tend to
haveamongthelowestlifeexpectancyandthehigh-
est rates of malnutrition-associated deaths. High
rates of malnutrition and mortality also appear to
occurincountrieswithlowmilkconsumptionrates,
leading to the question of whether milk-based pro-
biotic interventions could be used to prevent, or
treat,majorcausesofmorbidityandmortalityinthe
developing world. Reid described a project (West-
ernHeadsEast)runbystudents,staff,andfacultyat
WesternUniversityinCanadathatestablishedcom-
munity kitchens in Tanzania, Kenya and Rwanda
to prepare yogurt supplemented with L. rhamno-
sus GR-1 and other local micronutrients. The aim
of the project is to provide communities suffering
high rates of HIV and malnutrition with a sourceof
quality nutrition augmented by beneﬁcial bacteria.
PreliminarystudieswithL.rhamnosusGR-1have
shown beneﬁts for improving gut barrier function
andweightgain,reductionsinfungalinfectionsand
diarrhea episodes, and increases in overall energy
levels. These observations led Reid and collabora-
tors to conduct a randomized, double-blind, con-
trolledtrialinwhichHIVpatientswhohadnoprior
antiretroviral treatment were given yogurt fortiﬁed
solelywitheithermicronutrients(controlgroup)or
with both micronutrients and L. rhamnosus GR-1
(probiotic group) for 4 weeks. Although the results
from this pilot study did not show improvements
in CD4+ T cell counts due to probiotics, there were
unexpected social beneﬁts, such as economic em-
powerment of women involved with the commu-
nitykitchenefforts.Additionalstudiesareunderway
to evaluate other possible beneﬁts of L. rhamnosus
GR-1, including improved tolerance of HIV med-
ications, binding of aﬂatoxin B1, and reductions
in blood levels of certain toxic metals (mercury, ar-
senic,lead,andcadmium).Reidconcludedbysaying
that this grass-roots community effort and associ-
ated research should serve as a model to encour-
ageotherstohelpreducemalnutritionandimprove
health in other underdeveloped areas around the
world.
Hibberd discussed the use of probiotics to en-
hance immunizations in resource-limited settings.
The World Health Organization’s (WHO) Ex-
panded Programme on Immunization has helped
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increase childhood immunizations against diseases
such as polio, diphtheria, pertussis, measles, and
tetanus. While such efforts have saved an estimated
20 million children’s lives over the last 20 years, in
2011 over 23 million children received no immu-
nizations at all. A key reason for this is that gaps
exist in the cold-chain distribution systems needed
to preserve the potency of the vaccines. Hibberd
described her and collaborators’ efforts to create
vaccine-delivery vehicles by genetically engineering
the probiotic bacterium Bacillus subtilis to display
vaccine antigens; B. subtilis was chosen because it
can withstand extreme environmental conditions.
Hibberdandcolleagueshavecreatednon-injectable,
thermo-stable vaccines for tetanus and rotavirus,
with plans to extend to pertussis, diphtheria, and
other major causes of childhood diseases. The engi-
neered vaccines are stable at 45 ◦C without refrig-
eration for more than 1 year, and have been shown
in animal safety and immunogenicity studies to be
safe and capable of producing protective levels of
antibodies when administered intranasally, sublin-
gually, or transdermally.38,39 Plans are underway to
conduct testing of the B. subtilis vaccine platform
in humans under an IND, which could eventually
lead to a viable approach for providing childhood
vaccines that do not require the cold chain, needles,
or administration by skilled personnel, in resource-
limited settings.
Lactose intolerance continues to be a problem
for over 40 million people in the United States.
Research by Dennis Savaiano (Purdue University),
AndreaAzcaarate-Peril(UNCMicrobiomeCenter),
andToddKlaenhammer(NorthCarolinaStateUni-
versity) is evaluating the clinical effects of feed-
ing a highly puriﬁed, short-chain galactooligosac-
charide (GOS/RP-G28) on lactose intolerance and
changes in the composition of the colonic micro-
biota (using terminal restriction fragment length
polymorphisms (TRFLP) and 16S rRNA pyrose-
quencing). In a randomized, double-blinded study,
they fed GOS/RP-G28 to lactose-intolerant adults
for 36 days and collected stool samples at the start
of the study (day 0), after GOS treatment (day 36),
and30daysafterGOSfeedingwasstopped(day66);
consumption of dairy products was encouraged in
both placebo and intervention groups after day 36.
Lactose digestion and overall symptoms of lactose
intolerance improved in subjects fed GOS/RP-G28
comparedtoaplacebogroup;subjectsonGOSwere
sixtimesmorelikelytoclaimtheywerelactosetoler-
ant post-treatment. When compared to the placebo
group, subjects fed GOS/RP-G28 showed only mi-
nor changes in microbiota composition on day 36,
butstatisticallysigniﬁcantmajorshiftsinthemicro-
biotaoccurredatday66.Changesinthemicrobiota
by day 66 included increased abundance of Fae-
calibacterium prausnitzii,L a c t o b a c i l l a l e s ,a n dRose-
buria spp. within the Firmicutes phyla; increases in
(Lac+)OscillibacterandDoreaspp.;andareduction
in some Clostridia class members. Expanded stud-
ies are planned to conﬁrm these changes in the fe-
cal microbiota of lactose-intolerant individuals that
were clinically responsive to dietary adaptation to
GOS/RP-G28.
Jo¨ el Dor´ e (Institut National de la Recherche
Agronomique, France) provided an excellent
overview of research and clinical studies on the
anti-inﬂammatory properties of F. prausnitzii, and
described studies conducted by his group aimed
at evaluating the mechanisms of crosstalk between
F. prausnitzii and host cells that may underlie its
role as a mutualistic commensal. He set the stage by
pointingoutthatresearchstudiesconductedduring
the past decade have demonstrated an association
between certain chronic immune diseases and dys-
biosis of the intestinal microbiota40–42 Ar e c u r r e n t
theme in many of these studies is the observation
that such chronic immune disorders are associated
withthepresenceoflow-gradeinﬂammationonthe
hostsideandareductionofsomeimportantantimi-
crobial commensal species on the microbiome side.
Mostlikely,otherfactorssuchasdiet,geneticpredis-
position, environment, and lifestyle also contribute
to the low-grade inﬂammatory state and changes in
microbiota composition (Fig. ??). F. prausnitziii is
one example of a potentially beneﬁcial intestinal
commensal, based on anti-inﬂammatory proper-
ties demonstrated in preclinical studies.41 Levels of
F.prausnitziiarefoundinlowabundanceinpatients
with Crohn’s disease,40 colorectal cancer, obesity,43
or IBS.44 In one study, administration of F. praus-
nitzii provided protection from endoscopic inﬂam-
mationrelapse6monthsaftersurgeryin20patients
with active CD requiring ileocecal resection.41
Dor´ e and colleagues are also investigating
bacteria–cell crosstalk using a functional metage-
nomics approach to better understand how al-
tered intestinal ecology may contribute to a chronic
immune condition. Human cell lines have been
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Figure 6. Alterationsofthegutmicrobiotaandlow-gradeinﬂammationmaycontributetoacycleofeventsthatinducesachronic
state in immune-mediated diseases. Interventions that target the combined modulation of gut microbiota and inﬂammation may
be the most effective way to manage such conditions.
engineered with stably transfected reporter genes,
allowing them to assess modulation of transcrip-
tionr egulatorssuchasNF-B,AP-1,orPPAR-,or
productionofproteinssuchasTSLP,TGF-,orFiaf.
High-throughputscreeningofinteractionsbetween
over 20,000 metagenomic clones bearing large ge-
nomic inserts of culturable and noncultured bacte-
ria and human cells have allowed the identiﬁcation
ofseveralbioactiveclonesthatmodulatecellularac-
tivitieswithrelevancetoimmuneresponse,prolifer-
ation, or metabolism. The genes involved are iden-
tiﬁed and relevant bioactive signal molecules are
identiﬁed using biochemical or genetic approaches.
Results from such studies may help unravel mecha-
nismsbywhichcommensalbacteriamodulatecellu-
larfunctions,whichmayleadtoexplorationofways
to favorably modulate probiotic–host interactions.
Intheclosingpresentation,FredDegnan(King&
Spalding,LLP)discussedtheperspectivesoftheU.S.
FDA on clinical study requirements as it relates to
regulatory classiﬁcations for probiotic-containing
products. A probiotic product can be classiﬁed in
different regulatory categories depending on the
product’sintendeduse,includingdrug,food,medi-
calfood,foodadditive,ordietarysupplement.There
areimplicationsforeachclassiﬁcationinrelationto
the nature and degree of regulatory requirements
and,ultimately,forclaimsubstantiationandmarket
access.
As a general rule, the FDA determines the degree
of regulation for clinical trials and assigns product
classiﬁcations on the basis of the intended use for a
given product. The intended use of a product can
be determined by a number of factors, including
claims, labeling, promotions, and by endpoints of
clinicalinvestigation.Basedprimarilyonthesetypes
of communications, the product will be deemed a
drug, food, dietary supplement, or medical food.
Thevariousclaimstructureforthesedifferentprod-
ucts can be summarized as follows:
 Drug/Biological product: Focus is on the cure,
treatment, mitigation, or prevention of dis-
ease, although these products can also affect
the structure or function of the human body
(biological products are drugs derived from
live microorganisms).
 Foods or dietary supplements:
◦ Health or “qualiﬁed” health claim: Char-
acterizes the relationship between a nutri-
ent, dietary supplement, or food, and the
reduction in risk of a disease or health-
relatedcondition.Anapprovedhealthclaim
must be supported by “signiﬁcant scientiﬁc
agreement,” while “qualiﬁed” health claims
arebasedon“emerging”scientiﬁcevidence.
Both must be pre-reviewed by the FDA via
a petition process or on the basis of state-
ments by an authoritative body.
◦ Structure/function claim: Describes the ef-
fect of a food, food component, nutrient or
dietary ingredient on the “structure or any
function of the body.” May not imply or
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express usefulness in the cure, mitigation,
treatment or prevention of disease.
 Medical food: For a patient under medical su-
pervision for the “dietary management of a
disease or condition for which distinctive nu-
tritional requirements have been established
by medical evaluation” and which cannot be
addressed by the diet alone.
A clinical study involving an FDA-regulated arti-
cle can evoke certain requirements. If a company or
individual wishes to conduct a human study on a
probiotic intended for prevention or treatment of a
disease,theywillberequiredtofollowamorerigor-
ous regulatory pathway. Typically, this will require
ﬁling an IND application (21 CFR Part 312), which
must be submitted before initiating studies in hu-
mans.TheINDwillbeexpectedtocontainextensive
information for the review process, including, but
not limited to, a description of Institutional Review
Board review (21 CFR Part 56) and informed con-
sent (21 CFR Part 50); how the product is made, to
ensure that safe, high-quality manufacturing pro-
cesses are used; and, often, data from preclinical
animal toxicology studies to demonstrate that it is
safe to proceed with human clinical studies. As in
other countries, the regulatory system has been set
up so that only a drug, not a food, can treat, pre-
vent, or cure disease. Questions were raised during
the meeting as to why this bureaucratic distinction
still remains in place today.
Guidance issued by the FDA in October, 2010
on “Determining whether human research stud-
ies can be conducted without an IND”45 had par-
ticular relevance for studies involving probiotics.
This document included language suggesting that
an IND would be required for studies in which a
live organism (e.g., virus, bacterium, or fungus) is
administered to subjects to study “the pathogene-
sis of disease” or “the host response to the organ-
ism.” The strictest interpretation of this statement
could be that any probiotic investigation would re-
quire an IND. Other guidance by the FDA issued
in February 2012 focuses on clinical trials with live
bio-therapeutic agents,46 with speciﬁc reference to
languagebeing“applicable”totheprevention,treat-
ment,orcureofdisease.However,thisdocumentac-
knowledgesthatabasisexistsforconductinghuman
studies on food (including dietary supplements)
that do not require the same IND application pro-
cess as drug studies; such studies will need to avoid
drug-type endpoints. The intended use will dictate
regulation,butexamplesofappropriatefoodtargets
include human studies intended to establish health
claims, structure/function claims, or medical food
claims. In conclusion, to avoid FDA imposition of
a requirement for an IND, Degnan recommended
(1) conceiving and designing studies that consider
the intended use and a clear understanding of reg-
ulatory categories; (2) using caution in document-
ing/substantiating non-biological product use; and
(3) consulting with FDA’s Center for Food Safety
and Applied Nutrition.
Conclusions
The conference “Probiotics, Prebiotics, and the
Host Microbiome: The Science of Translation” pro-
vided a forum in which recent developments and
the potential beneﬁts of translating research ad-
vances in the human microbiome, probiotics, and
prebiotics into robust nutritional and therapeu-
tic applications to promote health were examined.
The number of genes in the microbiome is es-
timated to be more than 300-fold higher than
the total number of human genes, which high-
lights the existence of a highly complex micro-
biota ecosystem with the potential for profound
effectsonmetabolismandimmunefunction.Signif-
icantadvanceshavebeenachievedandfurtherstud-
ies will greatly enhance our understanding of the
humanmicrobiotaanditsroleinhealthanddisease
development.
It is well established that the intestinal micro-
biota plays a critical role in gastrointestinal devel-
opment and function while regulating host inﬂam-
matory responses and immune homeostasis.47,48 A
rapidly growing body of evidence now also indi-
cates that the microbiota acts as a metabolically ac-
tive organ, capable of interacting with several host
systems beyond the gastrointestinal tract, including
thebrain,urogenitaltract,andrespiratorytract.49–51
Recentresearchsuggeststhegutmicrobiotaiscapa-
ble of inﬂuencing fat storage and metabolism,52,53
which may position it as a key target in the ﬁght
against obesity in conjunction with dietary, exer-
cise, and other interventions. Disruptions in the
early programming of the gut microbiota or al-
terations of adult-like microbiota may contribute
to the development of obesity and T2D. Proposed
mechanisms include effects on hormone-based
14 Ann. N.Y. Acad. Sci. 1306 (2013) 1–17 C   2013 The Authors. Annals of the New York Academy of Sciences published by Wiley Periodicals,
Inc. on behalf of New York Academy of Sciences.Petschow et al. Probiotics, prebiotics, and the host microbiome
satiety,energysalvage,appetiteregulation,andLPS-
induced metabolic endotoxemia. The use of probi-
otics and prebiotics that target speciﬁc changes in
themicrobiotaanditscrosstalkwiththehosttoim-
prove lipid metabolism and insulin resistance are
exciting potential options for improving the man-
agementofwhatisarguablythe21stcentury’ smajor
public health issue.
The gut–brain axis is a highly complex sys-
tem comprising interactions that involve the au-
tonomic and enteric nervous systems, pituitary
and gut hormones, and gut inﬂammatory systems
that are capable of inﬂuencing nerve function and
pathways, and ultimately behavior. Central ner-
vous system wiring may be inﬂuenced by gut–brain
interactions early in life, and alterations in the mi-
crobiomemayinﬂuencebehaviorsrelatedtospeciﬁc
disease conditions. Examples include the possibili-
ties of either inﬂuencing the microbiota with pro-
biotics to modulate cholecystokinin (CCK) output,
which in turn regulates vagal afferent neuron trans-
missions involved in communicating satiety and
avoiding obesity, or providing prebiotics to encour-
agefermentativeproductionofSCFAsthatstimulate
releaseofguthormones,whichinturninﬂuencehy-
pothalamicneuronalactivityinvolvedwithappetite
regulation.
Many questions remain regarding the develop-
ment of the microbiota in the young infant, and
whether probiotic/prebiotic interventions at this
time would be effective in supporting the develop-
mentofalifelongmicrobiotaforhealth.Muchneeds
to be learned about how the microbiota is assem-
bled, what inﬂuences community structure succes-
sion, and which factors contribute to its long-term
stability in both health and illness. It seems likely
thatthefuturerolesofprobioticsandprebioticswill
gobeyondtraditionalgastrointestinalillnesses,par-
ticularly as the role of the microbiota and the CNS
and other organs is better understood. Novel appli-
cations in the future may include chronic immune
disorders, and anxiety-like behaviors or psychiatric
illness.Thedevelopmentofsuchproductsiscertain
to face increased scrutiny over costs and beneﬁts to
support decisions about utilization and reimburse-
ment for disease management. Inﬂuencing public
health policy to more effectively adopt the use of
such products will require clear understanding and
communication of the health beneﬁts, building the
will for change with providers and policy makers,
executing the changes in policy, and driving these
changes with strong, reproducible data.
As we get closer to understanding the potential
mechanisms by which particular probiotic organ-
ismsinteractwiththemicrobiota,itwillbeamissed
opportunityifthequalityofprobioticresearchstud-
ies does not improve to meet the needs for either
evidence-based medicine or nutrition. Standard-
ization of probiotic/prebiotic study methods and
protocols, clear understanding of the characteris-
tics, purity, and stability of test agents, and accurate
and balanced reporting of study results are urgently
needed. In parallel, it will be important to educate
healthcareprofessionals,regulatoryauthorities,and
the public to understand the appropriate use and
documented safety and beneﬁts of probiotic or pre-
biotic products. Presentations and discussions dur-
ing the conference reiterated that there is no opting
out of this paradigm shift, but rather a matter
of when and how the innovations from micro-
biota/microbiome and probiotic/prebiotic research
will become part of everyday life. For those in the
ﬁeld, the regulatory antiquity and recalcitrance of
many physicians to move from a pharmaceutical-
based patient-management perspective to a more
holisticonethatincludesrecommendationsoffood
and supplement-based products to both general
and patient populations remainamong theimpedi-
ments to progress. Meanwhile, regulatory issues on
pro-andprebioticsremainapointofconcern.High-
quality human research conducted on the general
population is required to convince regulators of the
legitimacy of health beneﬁts of foods. Many con-
vincing probiotic studies have been done on popu-
lationsthatareoutsidethescopeoffoodsorsupple-
ments. However, the safety and lack of side effects
for these products is a strong plus. Thus, it is in-
cumbent upon those in the ﬁeld to help strengthen
the body of evidence and merge the knowledge in a
manner that allows consumers and patients to reap
the beneﬁts sooner rather than later.
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